文献速递中枢神经肿瘤放疗放疗物理与技术

ATR抑制剂NVP-BEZ235与AZD6738系统给药后可有效穿透血脑屏障

ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration.
PubMed 文献 · Radiat Oncol · 2018-04-23

该研究在无瘤CD-1小鼠中腹腔注射NVP-BEZ235或AZD6738,用HPLC/MS测定血和脑内药物浓度,发现两药尤其AZD6738生物利用度高且脑穿透有效;但在原代胶质瘤起始细胞驱动的原位胶质瘤模型中,即使低剂量用药联合放疗,两药均未改善生存。

要点

  • NVP-BEZ235和AZD6738腹腔给药后均显示有效脑穿透,AZD6738尤为明显。
  • 在原位胶质瘤模型中,NVP-BEZ235+放疗、AZD6738+放疗及对照+放疗中位生存分别为99、86、101天。
  • 结果不支持将NVP-BEZ235或AZD6738作为胶质母细胞瘤的放疗增敏剂。

核心结论

  • ATR抑制剂NVP-BEZ235和AZD6738具备良好药代动力学和脑穿透性,但本研究结果不支持其作为胶质母细胞瘤放疗增敏剂。

研究设计与样本

  • 无瘤CD-1小鼠腹腔注射25 mg/Kg体重的NVP-BEZ235或AZD6738,于1、2、6、8小时采血并取脑。
  • 用高效液相色谱/质谱法测定血和脑组织中的药物浓度。
  • 在原代胶质瘤起始细胞驱动的原位胶质瘤小鼠模型中观察药物联合电离辐射的疗效。

主要发现

  • NVP-BEZ235和AZD6738腹腔给药后生物利用度升高,尤其AZD6738脑穿透有效。
  • 在原位胶质瘤模型中,对照+放疗、NVP-BEZ235+放疗、AZD6738+放疗组中位生存分别为101、99、86天。
  • 尽管使用低药物和放射剂量,NVP-BEZ235联合放疗组观察到相对于AZD6738+放疗和对照+放疗组的毒性趋势。

临床怎么用

  • 本研究提示NVP-BEZ235和AZD6738虽能入脑,但联合放疗未改善胶质瘤模型生存,不支持其作为胶质母细胞瘤放疗增敏剂的临床转化。

局限性

  • 研究使用低药物和放射剂量,且为初步动物实验,样本量未报告。
  • 生存结果仅显示中位值,未报告统计学比较和P值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ataxia Telangiectasia and Rad3 related protein (ATR) is a central mediator of the response to DNA damage that may cause the quiescent resistance of cancer initiating cells to genotoxic radiotherapy. NVP-BEZ235 is a dual PI3K/mTOR inhibitor that also effectively targets ATR with IC50 = 21 × 10- 9 M in cells. AZD6738 does not target significantly PI3K/mTOR-related kinases but specifically inhibits ATR with IC50 = 74 × 10- 9 M in cells. Both drugs have been proposed as radiosensitizers of different tumors including glioblastoma (GB), the most malignant brain tumor. In order to study the radiosensitizing properties of ATR inhibitors NVP-BEZ235 and AZD6738 towards GB, we have preliminarily investigated their capacity to penetrate the brain after systemic administration. Tumor-free CD-1 mice were inoculated i.p. with 25 mg/Kg body weight of NVP-BEZ235 or AZD6738. 1, 2, 6 and 8 h later, blood was collected by retro-orbital bleeding after which the mice were euthanized and the brains explanted. Blood and brain samples were then extracted and NVP-BEZ235 and AZD6738 concentrations determined by High Performance Liquid Chromatography/Mass Spectrometry. We found for NVP-BEZ235 and especially for AZD6738, elevated bioavailability and effective brain penetration after intraperitoneal administration. Albeit low drug and radiation dosages were used, a trend to toxicity of NVP-BEZ235 followed by ionizing radiation (IR) towards mice bearing primary glioma initiating cells (GIC)-driven orthotopic tumors was yet observed, as compared to AZD6738 + IR and vehicle+IR. Survival was never improved with median values of 99, 86 and 101 days for vehicle+IR, NVP-BEZ235 + IR and AZD6738 + IR-treated mice, respectively. Although the present results indicate favorable pharmacokinetics properties of ATR inhibitors NVP-BEZ235 and AZD6738, they do not lend support to their use as radiosensitizers of GB.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Fròsina G, Profumo A, Marubbi D, et al. ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration. Radiat Oncol. 2018. PMID: 29685176. doi:10.1186/s13014-018-1020-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。